公开(公告)号：WO2011049412A3

公开(公告)日：2011-10-13

申请号：PCT/KR2010007303

申请日：2010-10-22

Applicant: HANWHA CHEMICAL CORP ,  LEE JUNGTAE ,  MOON KYUNGDUK ,  YOON JIYONG ,  SUNG BYUNGJE ,  LEE DONGHEON ,  LEE DONGEUN ,  RYU SUYEON ,  SHIM HYUNBO ,  KANG KYUNG JAE

Inventor： LEE JUNGTAE ,  MOON KYUNGDUK ,  YOON JIYONG ,  SUNG BYUNGJE ,  LEE DONGHEON ,  LEE DONGEUN ,  RYU SUYEON ,  SHIM HYUNBO ,  KANG KYUNG JAE

IPC: C07K16/18 ,  A61K39/395 ,  A61P35/00 ,  C12N15/13 ,  G01N33/577

CPC classification number: C07K14/70542 ,  A61K2039/505 ,  C07K16/2836 ,  C07K2317/24 ,  C07K2319/30 ,  G01N33/57484 ,  G01N33/577 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/525 ,  G01N2333/70542 ,  G01N2800/24 ,  G01N2800/32

Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.

Abstract translation: 本发明涉及与人血管细胞粘附分子-1（VCAM-1）特异性结合以抑制白细胞与活化内皮细胞之间的粘附和白细胞通过活化内皮细胞的迁移的人重组单克隆抗体，以及预防性和治疗性 用于炎性疾病的组合物或包含其的癌症。 根据本发明的人重组单克隆抗体显示出对人内皮细胞上表达的VCAM-1具有强亲和力，并且有效地抑制了VCAM-1介导的白细胞和激活的内皮细胞之间的粘附和白细胞通过激活的内皮细胞的迁移，由此 用于预防和治疗炎症性疾病，例如哮喘和关节炎，移植排斥反应，心血管疾病和癌症。

公开(公告)号：WO2010114312A3

公开(公告)日：2010-10-07

申请号：PCT/KR2010/001988

申请日：2010-03-31

Applicant: HANWHA CHEMICAL CORPORATION ,  LEE, Jungtae ,  MOON, Kyungduk ,  YOON, Jiyong ,  SUNG, Byungje ,  LEE, Dongheon ,  LEE, Ilsun ,  LEE, Dongeun ,  RYU, Suyeon ,  PARK, Youngwoo ,  CHOI, So-Young ,  PARK, Jihyun ,  JANG, Myeounghee

Inventor： LEE, Jungtae ,  MOON, Kyungduk ,  YOON, Jiyong ,  SUNG, Byungje ,  LEE, Dongheon ,  LEE, Ilsun ,  LEE, Dongeun ,  RYU, Suyeon ,  PARK, Youngwoo ,  CHOI, So-Young ,  PARK, Jihyun ,  JANG, Myeounghee

IPC: C07K16/18 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.

公开(公告)号：WO2011049412A2

公开(公告)日：2011-04-28

申请号：PCT/KR2010/007303

申请日：2010-10-22

Applicant: HANWHA CHEMICAL CORPORATION ,  LEE, Jungtae ,  MOON, Kyungduk ,  YOON, Jiyong ,  SUNG, Byungje ,  LEE, Dongheon ,  LEE, Dongeun ,  RYU, Suyeon ,  SHIM, Hyunbo ,  KANG, Kyung Jae

Inventor： LEE, Jungtae ,  MOON, Kyungduk ,  YOON, Jiyong ,  SUNG, Byungje ,  LEE, Dongheon ,  LEE, Dongeun ,  RYU, Suyeon ,  SHIM, Hyunbo ,  KANG, Kyung Jae

IPC: C07K16/18 ,  C12N15/13 ,  G01N33/577 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K14/70542 ,  A61K2039/505 ,  C07K16/2836 ,  C07K2317/24 ,  C07K2319/30 ,  G01N33/57484 ,  G01N33/577 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/525 ,  G01N2333/70542 ,  G01N2800/24 ,  G01N2800/32 ,  Y02A50/412 ,  Y02A50/58

Abstract: The present invention relates to a human recombinant monoclonal antibody that specifically binds to human Vascular Cell Adhesion Molecule-1 (VCAM-1) to inhibit adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, and a prophylactic and therapeutic composition for inflammatory disease or cancer comprising the same. The human recombinant monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human endothelial cell, and effectively inhibits VCAM-1-mediated adhesion between leukocytes and activated endothelial cells and transmigration of leukocytes through the activated endothelial cells, thereby being used for the prevention and treatment of inflammatory disease such as asthma and arthritis, transplant rejection, cardiovascular disease, and cancer.

Abstract translation: 本发明涉及特异性结合人血管细胞粘附分子-1（VCAM-1）以抑制白细胞与激活的内皮细胞之间的粘附和通过活化的内皮细胞的白细胞迁移的人重组单克隆抗体，以及预防和治疗 包含其的炎性疾病或癌症的组合物。 根据本发明的人重组单克隆抗体显示出对人内皮细胞上表达的VCAM-1的强亲和力，并且有效抑制白细胞和激活的内皮细胞之间的VCAM-1介导的粘附和白细胞通过活化的内皮细胞的迁移，由此 用于预防和治疗炎性疾病如哮喘和关节炎，移植排斥反应，心血管疾病和癌症。

公开(公告)号：WO2009154969A3

公开(公告)日：2009-12-23

申请号：PCT/US2009/045255

申请日：2009-05-27

Applicant: FAIRCHILD SEMICONDUCTOR CORPORATION ,  LIU, Yong ,  QIAN, Qiuxiao ,  ZHANG, Jiang Yuan ,  SPEED, Mike ,  LEE, JungTae ,  CHUNG, Luke, H.

Inventor： LIU, Yong ,  QIAN, Qiuxiao ,  ZHANG, Jiang Yuan ,  SPEED, Mike ,  LEE, JungTae ,  CHUNG, Luke, H.

IPC: H01L25/07 ,  H01L25/11 ,  H01L23/34 ,  H01L23/36

Abstract: A molded, leadless packaged semiconductor multichip module includes 100 has four mosfets 10, 12, 14, 16 for a full bridge circuit. The mosfets may include two N- channel and two P-channel devices or four mosfets of the same type, but four N-channel are preferred. In module 100 there are two leadframes 30, 40 for assembling the mosfets. In particular, the two N-channel and two P-channel devices are disposed between two leadframes and encapsulated in an electrically insulating molding compound 84. The resulting package has four upper heat sinks 44.1-44.4 that are exposed in the molding compound 84 for transferring heat from the mosfets to the ambient environment. No wire bonds are required. This can significantly reduce the on resistance, RDSON- The top or source-drain lead frame 30 may be soldered to the sources and gates of the bridge mosfets.

公开(公告)号：WO2009154969A2

公开(公告)日：2009-12-23

申请号：PCT/US2009045255

申请日：2009-05-27

Applicant: FAIRCHILD SEMICONDUCTOR ,  LIU YONG ,  QIAN QIUXIAO ,  ZHANG JIANG YUAN ,  SPEED MIKE ,  LEE JUNGTAE ,  CHUNG LUKE H

Inventor： LIU YONG ,  QIAN QIUXIAO ,  ZHANG JIANG YUAN ,  SPEED MIKE ,  LEE JUNGTAE ,  CHUNG LUKE H

IPC: H01L25/07 ,  H01L23/34 ,  H01L23/36 ,  H01L25/11

CPC classification number: H01L23/49575 ,  H01L23/3107 ,  H01L23/49524 ,  H01L23/49551 ,  H01L23/49562 ,  H01L24/36 ,  H01L24/40 ,  H01L24/41 ,  H01L24/48 ,  H01L2224/40245 ,  H01L2224/45014 ,  H01L2224/48247 ,  H01L2224/4847 ,  H01L2224/48472 ,  H01L2224/73219 ,  H01L2224/73221 ,  H01L2924/00014 ,  H01L2924/01006 ,  H01L2924/01015 ,  H01L2924/01023 ,  H01L2924/01029 ,  H01L2924/01033 ,  H01L2924/01046 ,  H01L2924/01047 ,  H01L2924/01079 ,  H01L2924/01082 ,  H01L2924/014 ,  H01L2924/1306 ,  H01L2924/13091 ,  H01L2924/14 ,  H01L2924/181 ,  H01L2924/00 ,  H01L2924/00012 ,  H01L2224/45015 ,  H01L2924/207 ,  H01L2224/37099

Abstract: A molded, leadless packaged semiconductor multichip module includes 100 has four mosfets 10, 12, 14, 16 for a full bridge circuit. The mosfets may include two N- channel and two P-channel devices or four mosfets of the same type, but four N-channel are preferred. In module 100 there are two leadframes 30, 40 for assembling the mosfets. In particular, the two N-channel and two P-channel devices are disposed between two leadframes and encapsulated in an electrically insulating molding compound 84. The resulting package has four upper heat sinks 44.1-44.4 that are exposed in the molding compound 84 for transferring heat from the mosfets to the ambient environment. No wire bonds are required. This can significantly reduce the on resistance, RDSON- The top or source-drain lead frame 30 may be soldered to the sources and gates of the bridge mosfets.

Abstract translation: 包括100个的模制的无引线封装半导体多芯片模块具有用于全桥电路的四个mosfet 10,12,14,16。 MOSFET可以包括两个N沟道和两个P沟道器件或四个相同类型的MOSFET，但是优选四个N沟道。 在模块100中，存在用于组装mosfet的两个引线框30,40。 特别地，两个N沟道和两个P沟道器件设置在两个引线框之间并封装在电绝缘的模制化合物84中。所得到的封装具有四个上部散热器44.1-44.4，其暴露在模制化合物84中用于转移 从mosfet到周围环境的热量。 不需要引线键。 这可以显着降低导通电阻RDSON。顶部或源极 - 漏极引线框架30可以焊接到桥式MOSFET的源极和栅极。

公开(公告)号：WO2010114312A2

公开(公告)日：2010-10-07

申请号：PCT/KR2010001988

申请日：2010-03-31

Applicant: HANWHA CHEMICAL CORP ,  LEE JUNGTAE ,  MOON KYUNGDUK ,  YOON JIYONG ,  SUNG BYUNGJE ,  LEE DONGHEON ,  LEE ILSUN ,  LEE DONGEUN ,  RYU SUYEON ,  PARK YOUNGWOO ,  CHOI SO-YOUNG ,  PARK JIHYUN ,  JANG MYEOUNGHEE

Inventor： LEE JUNGTAE ,  MOON KYUNGDUK ,  YOON JIYONG ,  SUNG BYUNGJE ,  LEE DONGHEON ,  LEE ILSUN ,  LEE DONGEUN ,  RYU SUYEON ,  PARK YOUNGWOO ,  CHOI SO-YOUNG ,  PARK JIHYUN ,  JANG MYEOUNGHEE

IPC: C07K16/18 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2836 ,  A61K2039/505 ,  C07K14/70542 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.

Abstract translation: 本发明涉及特异性结合VCAM-1的人单克隆抗体以及用于治疗炎症性疾病或癌症的治疗组合物。 根据本发明的人单克隆抗体对在人或小鼠内皮细胞上表达的VCAM-1显示出强亲和力，有效抑制白细胞与表达VCAM-1的活化内皮细胞粘附，并且显示出低的免疫原性，从而用于治疗 的癌症或炎性疾病如哮喘，鼻炎，关节炎，多发性硬化，肠病，动脉硬化，心肌梗死和移植排斥。